Healthy men help scientists track how cenerimod exits the body
NCT ID NCT02914223
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study gave a single dose of a radiolabeled drug called cenerimod to 6 healthy men aged 45-65. The goal was to see how quickly and by what routes (urine, feces, breath) the drug leaves the body. It is a Phase 1 trial with no treatment benefit, purely to gather information for future research.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- cenerimod (a drug being tested for immune-related conditions)
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY SUBJECTS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
PRA Health Science
Groningen, 9728 NZ, Netherlands
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Radioactive tracer reveals the Body's journey of an experimental drug
- Can music lessons rewire Teens' social media habits?
- Can a Finger-Prick replace the lab draw? a device puts accuracy to the test
- Avocado at breakfast: a secret weapon for blood sugar and fullness?
- Sound waves as medicine: ultrasound may tame inflammation without drugs
- Broader pneumonia shield: new vaccine tested in children